Commentary: PCP4 inhibits the progression of prostate cancer through Ca2+/CAMKK2/AMPK/AR pathway - Top-Institutions - MDSpire

Commentary: PCP4 inhibits the progression of prostate cancer through Ca2+/CAMKK2/AMPK/AR pathway

  • By

  • Wujie Chen

  • Fajiang Qian

  • Fengtong Wang

  • Fuquan Yang

  • Yuqing Shen

  • Mingxia Ding

  • Yuan Liu

  • July 3, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    MSKCC
    MSKCC

    New York, New York

    Key Differentiators

    • Oncology

  • #3

    Roswell Park Comprehensive Cancer Center
    Roswell Park Comprehensive Cancer Center

    Buffalo, New York

    Key Differentiators

    • Oncology

Original Source(s)

Commentary: PCP4 inhibits the progression of prostate cancer through Ca2+/CAMKK2/AMPK/AR pathway

  • by Wujie Chen, Fajiang Qian, Fengtong Wang, Fuquan Yang, Yuqing Shen, Mingxia Ding, Yuan Liu

  • July 3, 2026

Related Content

A prediction model for urological tumor metastasis using liquid biopsy-derived biomarkers

Gamma knife radiosurgery for renal cell carcinoma brain metastases across systemic therapy eras: survival, intracranial failure, and lesion-level predictors

Correction: miR-1323 promotes cell migration in lung adenocarcinoma by targeting Cbl-b and is an early prognostic biomarker